Series D · Healthtech

Boehringer invests $50m in Click Therapeutics Series D

The investment accompanies the transfer of CT-155 commercialization responsibilities to Click.

Boehringer Ingelheim made a $50 million Series D investment in Click Therapeutics under an agreement announced on April 9. It also provided dedicated commercial funding, whose value was not disclosed.

The agreement transfers full product responsibility for CT-155, including commercial and marketing authorization rights, to Click. Boehringer will continue to lead completion of the ENSPIRUS study.

Click subsequently announced FDA clearance for CT-155, branded Motivista, on October 5. The company was preparing the prescription digital treatment for broader commercial availability.

Use of funds

Commercialize CT-155 as Click takes over product and marketing responsibilities.

Funding history

Series D · This round$50M

Sources

  1. Click and Boehringer announce Series D investmentclicktherapeutics.com · Apr 9, 2026
  2. clicktherapeutics.com